Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Finance
Blisibimod (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022

Blisibimod (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022 - new market research report published


Print article Print article
© companiesandmarkets.com

companiesandmarkets.com
companiesandmarkets.com
2014-03-24 04:57:01 - Blisibimod (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022 - a new market research report on companiesandmarkets.com

Blisibimod (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022 - Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can affect any organ or tissue and is the prototypic autoimmune disease. While SLE can affect multiple major organ systems in the body, one of its most severe manifestations includes renal (kidney) involvement, known as lupus nephritis (LN). The term LN refers to SLE patients with glomerulonephritis, and when the term LN is used, glomerular tissue injury in the kidneys is always involved. Renal injury without any glomerular involvement is classified as nephritis in a patient with SLE.

Anthera Pharmaceuticals is developing blisibimod as a potential treatment for autoimmune diseases, including SLE. Amgen initiated the

 

 

development of blisibimod, but in January 2008 Anthera Pharmaceuticals entered into a license agreement with Amgen for the exclusive and worldwide rights to develop and commercialize this product.

Scope

- Overview of SLE-LN, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Blisibimod including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Blisibimod for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for SLE-LN
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Blisibimod performance
- Obtain sales forecast for Blisibimod from 2012-2022 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..

About Us
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.com’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.


Author:
Mike King
e-mail
Web: www.companiesandmarkets.com
Phone: London: +44 (0) 203 086 8600

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com